|
rs12979860
|
|
Liver carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Sensitivity analyses suggested the robustness of the results in this meta-analysis.Both IL28B rs12979860 CC and rs8099917 TT genotypes are protective factors for the development of HCC among patients with HBV or HCV infection.
|
31568008 |
2019 |
|
rs12979860
|
|
Liver carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
IL28B rs12979860 polymorphism was significantly associated with HCC development after DAAs.
|
31826071 |
2019 |
|
rs12979860
|
|
Liver carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Liver cirrhosis, high APRI levels, and IL28B rs12979860 at baseline are independent risk factors for HCC development in patients without SVR after peg-IFN combination therapy.
|
29254684 |
2018 |
|
rs12979860
|
|
Liver carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
IL-28B rs12979860 TT genotype is more prevalent in patients with advanced fibrosis, cirrhosis and HCC stages.
|
29914308 |
2018 |
|
rs12979860
|
|
Liver carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study aimed to determine whether IL28B rs12979860 polymorphism is also associated with development of hepatocellular carcinoma both in chronic HCV infection and in non-viral-related cirrhosis.
|
27083168 |
2017 |
|
rs12979860
|
|
Liver carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Single nucleotide polymorphisms (SNPs) near the epidermal growth factor (EGF) (rs4444903), IL28B (rs12979860), and PNPLA3 (rs738409) loci are associated with treatment response, fibrosis, and hepatocellular carcinoma in non-transplant hepatitis C, but allograft population data are limited.
|
26854475 |
2016 |
|
rs12979860
|
|
Liver carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
the Interferon lambda (IFNL) polymorphisms genotypes (rs8099917, rs12979860 and rs12980275) and the presence of mutations in HCV core protein were analyzed in 59 patients with HCC, and also in 50 cirrhotic patients (without HCC).
|
27035616 |
2016 |
|
rs12979860
|
|
Liver carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our results demonstrated that patients bearing the genetic combination consisting of LMP-7 CA/AA [OR 4.75, 95% confidence interval (CI) 1.443-15.631, P = 0.007] and IL28B rs12979860 CT/TT (OR 6.00, 95% CI 1.603-22.455, P = 0.004) and positive for CMV viremia (OR 3.11, 95% CI 1.151-8.412, P = 0.02) were more likely to have HCC.
|
27726464 |
2016 |
|
rs12979860
|
|
Liver carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
IL28B genetic variations (rs12979860) were genotyped by pyrosequencing of DNA samples from 137 individuals with chronic HBV infection [50 inactive carriers (IC), 34 chronic hepatitis B (CHB), 27 cirrhosis, 26 hepatocellular carcinoma (HCC)], and 19 healthy controls.
|
25837166 |
2015 |
|
rs12979860
|
|
Liver carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Based on a retrospective study of patients treated for HCV infection, the IFNL3 rs12979860 CT and TT polymorphisms are associated with a risk for HCC, especially in patients without a SVR.
|
25460552 |
2015 |
|
rs12979860
|
|
Liver carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In participants with HCV genotype 1, unfavorable genotypes for HCV clearance near IFNL3 were associated with increased HCC risk, the adjusted odds ratio (95% CI) for rs12979860 and rs8099917 being 1.73 (1.00-2.99) and 1.84 (1.02-3.33), respectively.
|
26602024 |
2015 |
|
rs12979860
|
|
Liver carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our results suggest, for the first time, that no significant association were found between IL28B rs1</span>2979860 genotypes with the risk of developing HCC in Turkish patients.
|
25332265 |
2015 |
|
rs12979860
|
|
Liver carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Single nucleotide polymorphisms (SNPs) in the epidermal growth factor (EGF, rs4444903), patatin-like phospholipase domain-containing protein 3 (PNPLA3, rs738409) genes, and near the interleukin-28B (IL28B, rs12979860) gene are linked to treatment response, fibrosis, and hepatocellular carcinoma (HCC) in chronic hepatitis C. Whether these SNPs independently or in combination predict clinical deterioration in hepatitis C virus (HCV)-related cirrhosis is unknown.
|
25504078 |
2014 |
|
rs12979860
|
|
Liver carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We observed that IL-28B rs12979860 T/C polymorphism was positively associated with overall HCC risk (TT vs. CC: OR = 2.38; 95 %, 1.60-3.55; TT vs CT + CC: OR = 1.79; 95 %, 1.23-2.60).
|
24874053 |
2014 |
|
rs12979860
|
|
Liver carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In the overall analysis, the IL-28B rs12979860 T/C polymorphism was identified as a genetic risk factor for hepatitis virus-related HCC and LC development.
|
24085431 |
2013 |
|
rs12979860
|
|
Liver carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We have determined the rs12979860 single nucleotide polymorphism (SNP) upstream IL28B gene in two groups of patients with HCV-induced chronic liver disease: 1) 268 patients (159 men) with biopsy-proven chronic hepatitis C, to analyse its relation with biochemical, virological and histological features; and 2) 134 patients (97 men) with HCV-related hepatocellular carcinoma.
|
22666430 |
2012 |
|
rs12979860
|
|
Liver carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Currently, the role of IL28B polymorphism (rs12979860) in the development of hepatocellular carcinoma (HCC) is unclear, and only limited data are available on the course of HCV recurrence.
|
22411462 |
2012 |
|
rs12979860
|
|
Liver carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our results suggest that the IL28B rs12979860 C/T polymorphism might affect susceptibility to the chronic HBV infection and progression of HCC.
|
22310928 |
2012 |
|
rs12979860
|
|
Liver carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
To evaluate the role of host IL28B (interleukin 28B; interferon lambda 3) single nucleotide polymorphisms (SNPs) in predicting hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) susceptibility, three SNPs in the IL28B gene (rs12979860C/T, rs8099917G/T and rs12980275G/A) were examined in 330 subjects (including 154 HBV-related HCC patients, 86 non-HCC patients with chronic hepatitis B (CHB), 43 HBV self-limited infections and 47 healthy controls).
|
22310928 |
2012 |
|
rs12979860
|
|
Liver carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
IL-28B rs12979860 C/T polymorphism T allele is more prevalent in patients with viral cirrhosis due to HCV in comparison to other aetiologies and to patients with mild chronic hepatitis C. Among OLT patients, carriage of this allele seems to augment the risk of developing HCC.
|
21146242 |
2011 |